Downregulation of Ezrin in lung cancer cells has resulted in actin cytoskeleton rearrangements, reduced EGFR activity and phosphorylation levels of downstream signaling pathways, as well as a substantial reduction in cell migration and invasion (Chen et al., 2013; Saygideger-Kont et al., 2016). Here, EZR is linked to lung carcinoma.